Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio, Inc. director Jonathan Jian Wang submitted an initial Form 3 reporting no securities beneficially owned as of the event date 07/25/2025. The filing notes it was submitted late because the reporting person experienced delays obtaining EDGAR access codes; the form is signed by an attorney-in-fact on 08/15/2025. No non-derivative or derivative holdings are disclosed.
ImageneBio amended its current report to provide additional disclosure about the acquired business, Inmagene. The amendment adds Management's Discussion and Analysis for Inmagene and unaudited interim condensed financial statements covering the three- and six-month periods ended June 30, 2025 and 2024. The filing incorporates these items as Exhibits 99.3 and 99.4 and states it does not change any other previously reported items or discuss developments after the original report. The disclosure supplements the Original Report that had reported completion of the Merger.